ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive: ZNF224 has been demonstrated as well as a transcriptional repressor of c-MYC [151] and receptor tyrosine kinase AXL [150], which may confer drug resistance in chronic myeloid leukemia (CML) patients.